Search the Newsreel

Gilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat

Gilead Sciences maintains a wide economic moat due to strong profit margins from its HIV and hepatitis C virus portfolios. The company's future growth relies on continued innovation in HIV, successful oncology product launches, and strategic acquisitions. These factors are expected to drive mid-single-digit …

Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...

This article first appeared on GuruFocus. Total Product Sales (excluding Veklury): $7.6 billion, up 10% year-over-year. Total Product Sales (including Veklury): $7.6 billion, up 8% year-over-year. HIV Sales: $5.7 billion, up 12% year-over-year. Biktarvy Sales: $3.8 billion, up 7% year-over-year. PrEP Business Sales: Exceeded …

Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury drop

[ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha MORE ON GILEAD SCIENCES * Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript [https://seekingalpha.com/article/4930335-gilead-sciences-inc-gild-q2-2026-earnings-call-transcript] * Gilead Sciences, Inc. 2026 Q2 - Results - …

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent …

Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10%

Earnings Call Insights: Gilead Sciences (GILD) Q2 2026 MANAGEMENT VIEW * "Gilead has delivered another quarter of commercial excellence with base business sales up 10% year-over-year... driven by our HIV portfolio, Trodelvy and Livdelzi," said (Chairman & CEO Daniel O'Day), adding that "we are …

Gilead Sciences Q2 Earnings Call Highlights

Key Points Interested in Gilead Sciences, Inc.? Here are five stocks we like better. Base business sales rose 10% year over year to $7.6 billion, led by HIV, oncology and liver treatments. Gilead raised its full-year base business sales outlook to $29.8 billion–$30.1 billion …

Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Gilead Sciences (GILD) reported revenue of $7.8 billion, up 10.2% over the same period last year. EPS came in at -$6.75, compared to $2.01 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …

Gilead’s PrEP Business Hits Billion-Dollar Sales Mark

Gilead Sciences announced its second-quarter 2026 financial results, revealing that its PrEP (Pre-Exposure Prophylaxis) business has reached billion-dollar sales. The article highlights Gilead's financial performance and success in the commercial strategy for its infectious disease portfolio.

Informe de resultados: Gilead supera previsiones del Q2 2026

Gilead's High-Profile HIV Drug Beat, But That's Not What Grabbed Attention

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock edged lower late, still in a downtrend. Continue Reading

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

Gilead Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:GILD) 2026-08-04

This article provides details of Gilead Sciences, Inc.'s Q2 2026 earnings call presentation. The company reported an EPS of -$6.75, beating estimates by $0.50, and revenue of $7.80 billion, a 10.18% year-over-year increase, beating estimates by $400.50 million. The information is based on the …

AHF Crowns Gilead Corporate Welfare King

LOS ANGELES, August 04, 2026--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) condemns Gilead Sciences' greed as the drug company giant gloats over its latest quarterly financial results. The only thing new is the numbers detailing the parasitic profits from one of the worst epidemics to hit …

AWSX der Telegram-Trader.de: Gilead Sciences überzeugt mit starkem Wachstum - Prognose Kerngeschäft steigt

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

Gilead Sciences reported a $10.5 billion loss in the second quarter, primarily due to new research-and-development expenses from recent acquisitions. Despite this loss, the biopharmaceutical company saw revenue growth, largely driven by strong sales of its HIV products. Gilead also lowered its full-year forecast …

Gilead Revenue Jumps as Acquisitions Lead to Adjusted Loss

Gilead Sciences reported increased revenue in its second quarter, primarily driven by its strong HIV drug portfolio. Despite the revenue growth, the company posted an adjusted loss due to significant dealmaking costs associated with recent acquisitions. This indicates that while core business performance is …

Gilead Sciences Q2 2026: Revenue $7.8B, Product Sales $7.6B, EPS (GAAP) $(8.45)

Gilead Sciences reported Q2 2026 results with total revenues of $7.8 billion and product sales of $7.6 billion, marking a 10% year-over-year increase in product sales excluding Veklury. The company recorded GAAP diluted loss per share of $(8.45) due to significant acquired IPR&D expenses. …

Gilead second-quarter sales rise 8%, beating Wall Street estimates

By Deena Beasley Aug 4 (Reuters) - Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss ‌due to costs related to a series of acquisitions. The company's overall revenue …

Gilead Sales Beat Expectations on Strong HIV Prevention Growth

Gilead Sciences Inc. reported second-quarter sales that exceeded expectations, driven by strong performance in its HIV prevention and treatment drugs. The company's revenue increased by 10% to $7.8 billion, surpassing Wall Street's projection of $7.4 billion. Notably, quarterly sales for HIV prevention medicines surpassed …

Gilead Sciences Secures Landmark California Supreme Court Victory, Eliminating Nearly 23,000 "Duty to Innovate" Cases

Gilead Sciences won a significant victory in the California Supreme Court, which ruled that drug manufacturers do not owe a "duty to innovate" or develop alternative drugs for nondefective products. This decision dismisses nearly 23,000 consolidated cases against Gilead, preventing a new form of …

Gilead Sciences Stock (GILD) Opinions on Earnings Report

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here's what to expect. Gilead Sciences beat analysts' revenue expectations last quarter, reporting revenues of $6.96 billion, up 4.4% …

Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.

Gilead Sciences, Inc. has repurchased 2,693,030 shares for $355 million between April 1, 2026, and June 30, 2026, as part of its buyback plan announced on February 25, 2020. This brings the total repurchased shares to 51,569,874, representing 4.14% of its equity, for a …

Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q2 Revenue $7.80B, vs. FactSet Est of $7.40B

Gilead Sciences, Inc. announced its Q2 2026 revenue of $7.80 billion, surpassing FactSet's estimate of $7.40 billion. Despite this revenue beat, the company swung to an adjusted loss of $6.75 per share, compared to an estimated loss of $7.26 per share, primarily due to …

Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

LRE|Lead Real Estate Co Ltd|Price:1.260|

GILD|Gilead Sciences Inc|Kurs:133.210|Änderung %:+2.350

Gilead's $8.45 Q2 per-share loss reflects $11.2B in acquisition research costs

Nanjing Leads Biolabs Advances Autoimmune Drug LBL-051 Into First-in-Human Trial

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here's what to expect. Gilead Sciences beat analysts' revenue expectations last quarter, reporting revenues of $6.96 billion, up 4.4% …

California Supreme Court Rules for Gilead, Says Drugmakers Don’t Have ‘Duty to Innovate’

The California Supreme Court ruled in favor of Gilead Sciences, stating that drug manufacturers of safe drugs do not have a "duty to innovate" and develop potentially safer alternatives. This decision dismisses negligence claims from 24,000 patients using an HIV drug from Gilead, reversing …

Opinion | Gilead Beats the Plaintiff Bar

The California Supreme Court rejected a lawsuit against Gilead Sciences, providing a rare win for businesses against expansive liability theories. The suit, brought by 24,000 HIV patients, claimed Gilead delayed a new drug launch to maximize profits from an existing medicine. The court's decision …

California Supreme Court sides with Gilead in ‘duty’ to innovate case

The California Supreme Court has ruled in favor of Gilead Sciences in a significant case concerning the company's development of HIV medications. The 6-1 decision overturned a previous appeals court ruling, which had suggested Gilead could be held liable for allegedly slow-walking the development …

Gilead wins California Supreme Court decision that it calls 'a victory for all' drug developers

Gilead Sciences Inc. has won a significant case at the California Supreme Court concerning its best-selling HIV drugs. The company views this decision as a victory not only for itself but also for all drug developers working on new and improved medical treatments. This …

California's highest court rules for Gilead in 'duty to innovate' case

California's highest court has sided with Gilead Sciences in a landmark "duty to innovate" case, dismissing negligence claims from 24,000 HIV patients. The court ruled that drug manufacturers are not liable for failing to make a different, potentially safer drug available sooner, even if …

Gilead Sciences, Inc. (GILD) Stock Analysis: Solid Growth With A 20.69% Upside Potential

Nanjing Leads Biolabs Wins IND Nod for Bispecific Antibody in Metastatic Colorectal Cancer